Aktis Oncology, Inc.
AKTSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2027-12A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- Phase 1Recruitingreadout ~2027-12A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blue Owl Capital Holdings LpPassive (13G)May 14, 2026
- Mpm Bioventures 2018, L.P.Activist (13D)Jan 20, 2026
- Ecor1 Capital, LlcActivist (13D)Jan 20, 2026
- Eli Lilly & CoActivist (13D)Jan 15, 2026
- Vv Manager Ii, LlcActivist (13D)Jan 14, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Foley ToddDirector | Jan 12, 2026 | Conversion | 597,391 | — |
| Mpm Bioventures 2018, L.P.10% owner | Jan 12, 2026 | Conversion | 1.3M | — |
| Gadicke Ansbert10% owner | Jan 12, 2026 | Conversion | 1.3M | — |
| Ecor1 Capital, LlcDirector | Jan 12, 2026 | Conversion | 2.3M | — |
| Vida Ventures Ii, Llc10% owner | Jan 12, 2026 | Conversion | 4.9M | — |
| Kim Helen SusanDirector | Jan 12, 2026 | Conversion | 4.9M | — |
| Segal Lloyd MitchellDirector | Jan 12, 2026 | Conversion | 19,631 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 16.7 | -1.7% |
| Apr 30, 2026 | 2.6M | 10.0 | +9.8% |
| Apr 15, 2026 | 2.3M | 8.4 | +0.9% |
| Mar 31, 2026 | 2.3M | 3.0 | +99.1% |
| Mar 13, 2026 | 1.2M | 5.7 | +16.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Director / officer change · Regulation FD disclosureApr 16, 2026
- Results of operationsMar 30, 2026
- Amended charter or bylawsJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 14, 2026
- 10-QMay 11, 2026
- 8-KMay 11, 2026
- 4Apr 16, 2026
- 3Apr 16, 2026
- 8-KApr 16, 2026
- 8-KMar 30, 2026
- 10-KMar 30, 2026
- SCHEDULE 13DJan 20, 2026
- SCHEDULE 13DJan 20, 2026
- SCHEDULE 13DJan 15, 2026
- 3Jan 15, 2026
- 4Jan 14, 2026
- 4Jan 14, 2026
- 4Jan 14, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.